{"id":4234,"date":"2024-04-24T19:05:41","date_gmt":"2024-04-24T11:05:41","guid":{"rendered":"https:\/\/flcube.com\/?p=4234"},"modified":"2024-10-24T22:07:25","modified_gmt":"2024-10-24T14:07:25","slug":"lepu-medical-technology-reports-2023-revenues-of-rmb-7-98-billion-marking-a-24-78-yoy-decrease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=4234","title":{"rendered":"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease"},"content":{"rendered":"\n

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003<\/a>) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD 170 million), down 42.91% YOY.<\/p>\n\n\n\n

The medical device segment recorded revenues of RMB 3.67 billion, a decline of 37.5% YOY. The in vitro diagnostic business had seen significant sales from emergency rapid testing kits and PCR equipment in the same period of the previous year. Excluding the in vitro diagnostic business, the segment’s operating revenue increased by 6.7% compared to the same period last year. The pharmaceutical sector’s operating revenue was RMB 3.04 billion, down 11.47%, with formulated drugs recording an operating income of RMB 2.63 billion, a decrease of 11.9% YOY. Active pharmaceutical ingredients saw an operating revenue of RMB 410.63 million, down 8.6% YOY. The medical services and health management sector achieved revenues of RMB 1.26 billion, a decrease of 2.37% YOY, with Hefei High-Tech Cardiovascular Hospital’s revenue increasing by 42.45% YOY. Excluding emergency-related revenue, the sector’s operating revenue increased by 6.53% YOY.<\/p>\n\n\n\n

As of December 31, 2023, Lepu Medtech holds 609 medical approvals in China, including Class II and Class III, 241 CE marks, and 33 FDA certifications.<\/p>\n\n\n\n

Looking ahead, Lepu Medtech will focus on several sectors: \u2460 Active equipment and passive consumables for various subfields of cardiovascular implant intervention, including coronary intervention, peripheral implant intervention, electrophysiology, etc.; \u2461 Tissue regeneration engineering and plant intervention with development platforms for hydrogels, animal source patches, collagen, etc.; \u2462 Biodegradable materials and plant intervention with approvals and launches of coronary bioabsorbable stents, biodegradable occluders, and biodegradable patent foramen ovale occluders in China; \u2463 Artificial intelligence (AI) in cardiovascular disease applications, with AI integration in monitoring vital signs, detecting blood biomarkers, and medical imaging related to cardiovascular transplantation in chronic disease patients.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,374,864],"class_list":["post-4234","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-lepu-medical-technology","tag-she-300003"],"yoast_head":"\nLepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD 170 million), down 42.91% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=4234\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=4234\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-24T11:05:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T14:07:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4234#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4234\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease\",\"datePublished\":\"2024-04-24T11:05:41+00:00\",\"dateModified\":\"2024-10-24T14:07:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4234\"},\"wordCount\":310,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"Lepu Medical Technology\",\"SHE: 300003\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4234#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4234\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=4234\",\"name\":\"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-24T11:05:41+00:00\",\"dateModified\":\"2024-10-24T14:07:25+00:00\",\"description\":\"China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD 170 million), down 42.91% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4234#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4234\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4234#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease - Insight, China's Pharmaceutical Industry","description":"China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD 170 million), down 42.91% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=4234","og_locale":"en_US","og_type":"article","og_title":"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=4234","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-24T11:05:41+00:00","article_modified_time":"2024-10-24T14:07:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=4234#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=4234"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease","datePublished":"2024-04-24T11:05:41+00:00","dateModified":"2024-10-24T14:07:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=4234"},"wordCount":310,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","Lepu Medical Technology","SHE: 300003"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=4234#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=4234","url":"https:\/\/flcube.com\/?p=4234","name":"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-24T11:05:41+00:00","dateModified":"2024-10-24T14:07:25+00:00","description":"China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD 170 million), down 42.91% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=4234#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=4234"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=4234#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4234"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4234\/revisions"}],"predecessor-version":[{"id":9352,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4234\/revisions\/9352"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}